These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19026169)

  • 1. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women.
    Qin YJ; Zhang ZL; Zhang H; Hu WW; Liu YJ; Hu YQ; Li M; Gu JM; He JW
    Acta Pharmacol Sin; 2008 Dec; 29(12):1493-8. PubMed ID: 19026169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
    Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
    J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
    Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Traditional and novel bone remodeling markers in premenopausal and postmenopausal women.
    Botella S; Restituto P; Monreal I; Colina I; Calleja A; Varo N
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1740-8. PubMed ID: 24001743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b.
    Ohashi T; Igarashi Y; Mochizuki Y; Miura T; Inaba N; Katayama K; Tomonaga T; Nomura F
    Clin Chim Acta; 2007 Feb; 376(1-2):205-12. PubMed ID: 17045980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
    Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
    Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
    Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
    Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
    Brady JJ; Crowley RK; Murray BF; Kilbane MT; O'Keane M; McKenna MJ
    Ir J Med Sci; 2014 Mar; 183(1):47-52. PubMed ID: 23737138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
    Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
    Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
    Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
    Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
    Uchida K; Nakanishi M; Yoh K
    Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related changes of serum bone alkaline phosphatase and cross-linked C-telopeptides of type I collagen and the relationship with bone mineral density in Chinese women.
    Shan PF; Wu XP; Zhang H; Luo XH; Cao XZ; Xie H; Liu SP; Pi YZ; Fang TY; Liu H; Chen ZH; Zhong N; Liao EY
    Clin Chim Acta; 2006 Apr; 366(1-2):233-8. PubMed ID: 16330011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in Postmenopausal Osteoporosis.
    Wu Q; Zhong ZM; Pan Y; Zeng JH; Zheng S; Zhu SY; Chen JT
    Med Sci Monit; 2015 Aug; 21():2428-32. PubMed ID: 26286507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.